Castleman’s disease: an entity forgotten in ENT

Authors

  • Mohamed Riyas Ali Department of ENT, Maulana Azad Medical College, New Delhi, India
  • Vikram Wadhwa Department of ENT, Maulana Azad Medical College, New Delhi, India
  • Ravi Meher Department of ENT, Maulana Azad Medical College, New Delhi, India
  • Reena Tomar Department of Pathology, Maulana Azad Medical College, New Delhi, India
  • Karishma Singh Department of ENT, Maulana Azad Medical College, New Delhi, India
  • Nivea Singh Department of ENT, Maulana Azad Medical College, New Delhi, India

DOI:

https://doi.org/10.18203/issn.2454-5929.ijohns20211593

Keywords:

Retropharyngeal mass, Trans oral approach, Castleman’s disease

Abstract

Castleman’s disease (CD) usually presents as localized or systemic lymphadenopathy or as an extra nodal mass. The usual site of presentation are mediastinum, retroperitoneum, axilla and mesentery. Only 3 cases of CD have been reported in retro pharyngeal space. We report a case of 20 year old male patient with retropharyngeal mass. He presented with difficulty in swallowing, change in voice and respiratory distress. The mass was removed in-toto transorally after performing elective tracheostomy. The histopathological findings were consistent with hyaline vascular type of CD. He was decannulated after two day and postoperative period was uneventful. Postoperative CT imaging confirmed the complete excision of tumor and patient is on follow up, with no signs of recurrence. The presentation of tumour in the retropharyngeal space which is a rare site of occurrence add to the uniqueness of this case. Unicentric CD has an excellent prognosis and surgery is the management of choice. Its clinical features, histological subtypes, treatment modalities and prognosis are discussed.

Metrics

Metrics Loading ...

References

Castleman B, Iverson L, Menendez VP. Localized mediastinal lymph-node hyperplasia resembling thymoma. Cancer. 1956;9(4):822-30.

Yoshizaki K, Matsuda T, Nishimoto N, Kuritani T, Taeho L, Aozasa K, et al. Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease. Blood. 1989;74(4):1360-7.

Nishimoto N, Kanakura Y, Aozasa K, Johkoh T, Nakamura M, Nakano S, et al. Humanized anti- interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood. 2005;106(8):2627-32.

Dispenzieri A, Armitage JO, Loe MJ, Geyer SM, Allred J, Camoriano JK, et al. The clinical spectrum of Castlemans disease. Am J Hematol. 2012;87(11):997-1002

Mallik MK, Kapila K, Das DK, Haji BE, Anim JT. Cytomorphology of hyaline vascular Castleman’s disease: a diagnostic challenge. Cytopathology. 2007;18:168-74

Venkataramana CG, Kini H, Saha D, Rai S, Adiga DSA, Rao R, et al. Histomorphologic Spectrum in Hyaline Vascular Variant of Castleman Disease. J Clin Diagn Res. 2017;11(8):1-4.

Downloads

Published

2021-04-23

Issue

Section

Case Reports